More Australian children living with spinal muscular atrophy can now access a potentially lifesaving gene therapy, after the federal government expanded its PBS listing to cover kids up to 21 kilograms, not just babies under nine months.
Zolgensma is a one off gene therapy that targets the underlying cause of the condition. Without the PBS subsidy the treatment can cost patients more than $2.5 million.
Spinal muscular atrophy affects the nerves that control muscle movement and left untreated is the leading genetic cause of death in children under two. Up to five children a year are expected to benefit from the expanded listing, which took effect from 1 November.
Get the Lane Cove news in your inbox every Thursday.
Support independent local news
In the Cove is 100% free to read, with no paywall, and it always will be. We write for the community, from within the community. If you value local news, chipping in helps keep it coming.
Proud member of LINA, the Local & Independent News Association. Want to reach locals?